BNP Paribas Financial Markets’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $65.7M | Buy |
1,156,960
+1,047,578
| +958% | +$46.4M | 0.02% | 628 |
|
|
2026
Q1 | $3.25M | Sell |
109,382
-556,413
| -84% | -$16.6M | ﹤0.01% | 2344 |
|
|
2025
Q4 | $25.4M | Buy |
665,795
+100,198
| +18% | +$3.26M | 0.01% | 1047 |
|
|
2025
Q3 | $13.5M | Buy |
565,597
+390,564
| +223% | +$7.34M | 0.01% | 1354 |
|
|
2025
Q2 | $2.59M | Buy |
175,033
+27,919
| +19% | +$463K | ﹤0.01% | 2300 |
|
|
2025
Q1 | $2.64M | Sell |
147,114
-1,062,696
| -88% | -$21.6M | ﹤0.01% | 2192 |
|
|
2024
Q4 | $21.1M | Buy |
+1,209,810
| New | +$21.4M | 0.01% | 991 |
|
|
2022
Q4 | – | Sell |
-75,454
| Closed | -$1.86M | – | 4615 |
|
|
2022
Q3 | $1.86M | Buy |
+75,454
| New | +$1.95M | ﹤0.01% | 2012 |
|
|
2020
Q4 | – | Sell |
-12,512
| Closed | -$231K | – | 4223 |
|
|
2020
Q3 | $231K | Buy |
12,512
+8,961
| +252% | +$174K | ﹤0.01% | 2692 |
|
|
2020
Q2 | $72.5K | Sell |
3,551
-17,510
| -83% | -$279K | ﹤0.01% | 2893 |
|
|
2020
Q1 | $307K | Buy |
21,061
+16,228
| +336% | +$244K | ﹤0.01% | 2632 |
|
|
2019
Q4 | $68.6K | Sell |
4,833
-1,731
| -26% | -$22.1K | ﹤0.01% | 3487 |
|
|
2019
Q3 | $76.1K | Buy |
6,564
+1,954
| +42% | +$32.3K | ﹤0.01% | 3265 |
|
|
2019
Q2 | $92.6K | Sell |
4,610
-3,979
| -46% | -$78.6K | ﹤0.01% | 3079 |
|
|
2019
Q1 | $194K | Buy |
8,589
+8,579
| +85,790% | +$190K | ﹤0.01% | 2726 |
|
|
2018
Q4 | $226 | Sell |
10
-1,294
| -99% | -$32.2K | ﹤0.01% | 4085 |
|
|
2018
Q3 | $37.5K | Hold |
1,304
| – | – | ﹤0.01% | 3167 |
|
|
2018
Q2 | $35.5K | Sell |
1,304
-7,297
| -85% | -$194K | ﹤0.01% | 3257 |
|
|
2018
Q1 | $192K | Buy |
8,601
+595
| +7% | +$14.2K | ﹤0.01% | 2813 |
|
|
2017
Q4 | $169K | Buy |
8,006
+4,200
| +110% | +$96K | ﹤0.01% | 3050 |
|
|
2017
Q3 | $94.7K | Sell |
3,806
-269
| -7% | -$5.92K | ﹤0.01% | 2806 |
|
|
2017
Q2 | $79K | Buy |
4,075
+3,850
| +1,711% | +$69.8K | ﹤0.01% | 2935 |
|
|
2017
Q1 | $4.15K | Sell |
225
-1,807
| -89% | -$35.3K | ﹤0.01% | 3351 |
|
|
2016
Q4 | $38.5K | Sell |
2,032
-446
| -18% | -$9.12K | ﹤0.01% | 2944 |
|
|
2016
Q3 | $55.5K | Buy |
2,478
+1,080
| +77% | +$20.6K | ﹤0.01% | 2388 |
|
|
2016
Q2 | $24.9K | Sell |
1,398
-46,795
| -97% | -$757K | ﹤0.01% | 2509 |
|
|
2016
Q1 | $658K | Sell |
48,193
-55,261
| -53% | -$838K | ﹤0.01% | 1121 |
|
|
2015
Q4 | $2M | Buy |
103,454
+78,672
| +317% | +$1.57M | ﹤0.01% | 912 |
|
|
2015
Q3 | $502K | Buy |
24,782
+11,873
| +92% | +$352K | ﹤0.01% | 1358 |
|
|
2015
Q2 | $428K | Buy |
12,909
+2,410
| +23% | +$66K | ﹤0.01% | 1399 |
|
|
2015
Q1 | $252K | Buy |
10,499
+499
| +5% | +$7.61K | ﹤0.01% | 1498 |
|
|
2014
Q4 | $122K | Buy |
10,000
+8,628
| +629% | +$89.3K | ﹤0.01% | 1462 |
|
|
2014
Q3 | $12.4K | Buy |
+1,372
| New | +$16.1K | ﹤0.01% | 3479 |
|
Other funds holding TVTX
VCM
RSCM
SIMG
EA
BNP Paribas Financial Markets's TVTX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Travere Therapeutics (TVTX) stake by 958% in Q2 2026, buying an estimated $46.4M and bringing the position to 1,156,960 shares worth $65.7M. The position accounts for 0.02% of the portfolio, ranked #628.
BNP Paribas Financial Markets first reported a position in TVTX in Q3 2014 and has held it in 33 quarters since. 257 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- BNP Paribas Financial Markets held 1,156,960 shares of Travere Therapeutics worth $65.7M as of Q2 2026.
- BNP Paribas Financial Markets bought 1,047,578 Travere Therapeutics shares in Q2 2026, an estimated $46.4M.
- Travere Therapeutics made up 0.02% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #628 holding.
- BNP Paribas Financial Markets first reported a position in Travere Therapeutics in Q3 2014 and has held it in 33 quarters since.
- 257 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.